Literature DB >> 1133150

Serum immunoreactive parathyroid hormone and 25-hydroxyvitamin D in patients with uremic bone diseases.

D J Baylink, D J Sherrard, L Shen, N A Maloney, J E Wergedal.   

Abstract

Bone histologic parameters and serum iPTH and 25-OHD were measured in 20 patients with end-stage renal failure treated with hemodialysis. By bone histologic criteria, the patients were divided into three groups: mild, osteomalacic, and fibrotic. The increase in serum iPTH was much greater in the fibrotic group than in the mild or osteomalacic groups. In the uremic patients as a group, there were significant correlations between serum iPTH and both percent marrow fibrosis and percent resorbing surface. In the mild and fibrotic groups together, serum iPTH was also correlated with percent forming surface. This and other findings suggested that most of the bone changes in the mild and fibrotic groups could be explained by excess PTH. The difference in bone changes and in serum iPTH between the mild and fibrotic groups could be related to our eariler findings that duration of renal disease was much greater in the fibrotic than in the mild group. The lowest increment in serum iPTH was found in the osteomalacic group. In this group, percent resorbing surface was not increased and there was only a slight increase in marrow fibrosis. Thus in all three groups, serum iPTH appeared to reflect parathyroid status. The cause of the elevated serum iPTH and for the intergroup differences was not apparent inasmuch as serum calcium was normal in all three groups. Serum 25-OHD was significantly elevated in the osteomalacic and fibrotic groups. Because none of our patients had received preparations containing vitamin D, the elevated serum 25-OHD in the osteomalacic and fibrotic groups is consistent with altered vitamin D metabolism in these two groups. There was a direct relationship between percent osteroid area and serum 25-OHD. However, whether or not altered vitamin D metabolism contributed to the mineralization defect in uremic bone disease could not be established.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133150     DOI: 10.1210/jcem-40-6-1009

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.

Authors:  W E Rutherford; P Bordier; P Marie; K Hruska; H Harter; A Greenwalt; J Blondin; J Haddad; N Bricker; E Slatopolsky
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

2.  Inhibition of in vitro mineralization by aluminum in a clonal osteoblastlike cell line, MC3T3-E1.

Authors:  K Ikeda; T Matsumoto; K Morita; K Kurokawa; E Ogata
Journal:  Calcif Tissue Int       Date:  1986-11       Impact factor: 4.333

3.  Metabolic consequences of bilateral nephrectomy.

Authors:  G R Catto; N Muirhead
Journal:  Br Med J (Clin Res Ed)       Date:  1984-07-21

4.  A quantitative histomorphometric comparison of 40 micron thick Paragon sections with 5 micron thick Goldner sections in the study of undecalcified bone.

Authors:  A J Felsenfeld; J M Harrelson; R A Gutman
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

Review 5.  [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].

Authors:  E Ritz; W Kreusser; R Boland; J Bommer
Journal:  Klin Wochenschr       Date:  1979-10-01

6.  In vitro synthesis of 1 alpha,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol by isolated calvarial cells.

Authors:  R T Turner; J E Puzas; M D Forte; G E Lester; T K Gray; G A Howard; D J Baylink
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.